Enanta Pharmaceuticals

Focus: Enanta Pharmaceuticals is a small molecule-focused pharmaceutical company headquartered in Watertown, Massachusetts, specializing in neurology therapeutics.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Enanta Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Enanta Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

45 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EDP-938

RSV Infection

Phase 1

Clinical Trials (1)

NCT03384823A Study of EDP-938 in Healthy Subjects

Phase 1

Help build intelligence for Enanta Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused portfolio in neurology offers deep disease expertise and specialized career development
Small molecule platform provides broad medicinal chemistry and drug design experience
Mid-scale company structure enables cross-functional visibility and direct impact on programs

Watch Out For

Zero active clinical trials and empty pipeline suggest minimal near-term clinical catalysts and potential program delays
No disclosed financial data, active hiring, or recent news creates visibility risk around company stability and growth trajectory

Generated by Claude from Enanta Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DEB025

Hepatitis C Virus

Phase 1

Clinical Trials (1)

NCT02173574Two-way Interaction Between Alisporivir and EDP239

Phase 1

EDP-978

Chronic Inducible Urticaria

Phase 1

Clinical Trials (1)

NCT07540910A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

Phase 1

EDP-322

Skin and Soft Tissue Infections

Phase 1

Clinical Trials (1)

NCT00989872Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

Phase 1

EDP-305

NASH - Nonalcoholic Steatohepatitis

Phase 1

Clinical Trials (1)

NCT03783897A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

Phase 1

EDP-323

RSV Infection

Phase 1

Clinical Trials (1)

NCT05587478A Study of EDP-323 in Healthy Subjects

Phase 1

EDP-494

Hepatitis C

Phase 1

Clinical Trials (1)

NCT02652377EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Phase 1

EDP-938

Respiratory Syncytial Virus (RSV)

Phase 1

Clinical Trials (1)

NCT04927793Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Phase 1

EDP-788

Healthy

Phase 1

Clinical Trials (1)

NCT02255968Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

Phase 1

EDP-938

RSV Infection

Phase 1

Clinical Trials (1)

NCT04871724Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects

Phase 1

EDP-514

Hepatitis B

Phase 1

Clinical Trials (1)

NCT04783753Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

Phase 1

EDP-305

NASH - Nonalcoholic Steatohepatitis

Phase 1

Clinical Trials (1)

NCT03748628Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects

Phase 1

intraconazole

NASH - Nonalcoholic Steatohepatitis

Phase 1

Clinical Trials (1)

NCT03213145Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

Phase 1

EDP-322

MRSA, SSTI

Phase 1

Clinical Trials (1)

NCT00990145Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

Phase 1

EDP-235

COVID-19

Phase 1

Clinical Trials (1)

NCT05594602Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Phase 1

EDP-788

Safety in Normal Volunteers

Phase 1

Clinical Trials (1)

NCT01999725Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

Phase 1

EDP-721

Chronic Hepatitis B Virus Infection

Phase 1

Clinical Trials (1)

NCT04971512A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Phase 1

EDP-938

RSV Infection

Phase 1

Clinical Trials (1)

NCT03755778Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

Phase 1

Fluconazole

NASH - Nonalcoholic Steatohepatitis

Phase 1

Clinical Trials (1)

NCT03610945Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

Phase 1

zelicapavir

RSV Infection

Phase 1

Clinical Trials (1)

NCT06601192A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Phase 1

EDP 305

NASH

Phase 1

Clinical Trials (1)

NCT03207425A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Phase 1

EDP239

Hepatitis C

Phase 1

Clinical Trials (1)

NCT01856426Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Phase 1

EDP 305

Presumptive NAFLD

Phase 1

Clinical Trials (1)

NCT02918929A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Phase 1

Midazolam

NASH

Phase 1

Clinical Trials (1)

NCT03187496Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

Phase 1

EDP-938

RSV Infection

Phase 1

Clinical Trials (1)

NCT03750383Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

Phase 1

EDP-514

Chronic HBV Infection

Phase 1

Clinical Trials (1)

NCT04470388A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Phase 1

EDP-514

Chronic HBV Infection

Phase 1

Clinical Trials (1)

NCT04008004A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Phase 1

EDP-323

RSV Infection

Phase 1

Clinical Trials (1)

NCT06917508A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Phase 1

EDP-297

NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

Phase 1

Clinical Trials (1)

NCT04559126A Study of EDP-297 in Healthy Subjects

Phase 1

EDP-323

RSV Infection

Phase 1

Clinical Trials (1)

NCT06847464A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Phase 1

EDP-235

COVID-19

Phase 1

Clinical Trials (1)

NCT05594615Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

Phase 1

EDP-938

RSV Infection

Phase 1

Clinical Trials (1)

NCT04498741Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Phase 1

EDP-235

SARS CoV 2 Infection

Phase 1

Clinical Trials (1)

NCT05246878A Study of EDP-235 in Healthy Subjects

Phase 1

EDP-305 Dose 1

Non-Alcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT03421431A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Phase 2

EDP-938

Respiratory Syncytial Virus (RSV)

Phase 2

Clinical Trials (1)

NCT04816721A Study to Evaluate EDP 938 Regimens in Children With RSV

Phase 2

EDP-938

Respiratory Syncytial Virus Infections

Phase 2

Clinical Trials (1)

NCT04633187Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract

Phase 2

EDP-323 Dose Regimen 1

RSV Infection

Phase 2

Clinical Trials (1)

NCT06170242A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Phase 2

EDP-938 Dose 1

RSV Infection

Phase 2

Clinical Trials (1)

NCT03691623A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

Phase 2

EDP-420 / Duration of Treatment - 3 days

Community Acquired Pneumonia

Phase 2

Clinical Trials (1)

NCT00270517Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia

Phase 2

EDP-305 1 mg

Primary Biliary Cholangitis

Phase 2

Clinical Trials (1)

NCT03394924A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Phase 2

EDP-305 1.5 mg

Non-Alcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT04378010A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

Phase 2

EDP-235

COVID-19

Phase 2

Clinical Trials (1)

NCT05616728A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

Phase 2

EDP-938

RSV Infection

Phase 2

Clinical Trials (1)

NCT05568706A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Phase 2

EDP-938

Respiratory Syncytial Virus

Phase 2

Clinical Trials (1)

NCT04196101A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

Phase 2

zelicapavir

RSV Infection

Phase 2

Clinical Trials (1)

NCT07482657A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Phase 2